You are here

Article Text

Article menu

Download PDFPDF

Letter
Sacubitril, valsartan and SARS-CoV-2
Free
  1. Antonio Vitiello1,
  2. Raffaele La Porta2,
  3. Francesco Ferrara1
  1. 1Pharmaceutical department, USL 1 Umbria, Perugia, Italy
  2. 2Pathology department, ASUR Marche, Ancona, Italy
  1. Correspondence to Dr Antonio Vitiello, Pharmaceutical department, USL 1 Umbria, Perugia 06121, Italy; antonio.vitiello2{at}uslumbria1.it
View Full Text

http://dx.doi.org/10.1136/bmjebm-2020-111497

Statistics from Altmetric.com

    Dear Editor,

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) is responsible for the current global pandemic. To date, no antivirals directed against the virus or effective vaccines are available.1 It is essential to recognise the risk factors and components that may play a protective role. There is no clear evidence on the correlation between changes in the renin–angiotensin system (RAS) by treatment with ACEIs, ARBs or DRis and COVID-19 infection.2–4 Randomised controlled trials are needed to verify the involvement of COVID-19 viral infection and chronic treatment with these drugs. A possible scientific hypothesis to investigate is the role …

    View Full Text

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.